As a first adopter of new international cross-containment guidelines recommended by ISPE, OsoBio expertly manages the risks posed by potent and cytotoxic compounds and DEA scheduled substances, successfully balancing the need for product quality and operator safety.
Because of our expertise in complex and difficult products, OsoBio works with nearly every category* of biological or pharmaceutical agent – and continually produces excellent regulatory compliance and quality assurance results.
If you have an especially challenging project, let us help. Our team of experienced professionals will craft an innovative solution that resolves your problem and positions your project for success.
OsoBio’s commercial manufacturing services include:
OsoBio is making significant capital investments in its manufacturing facilities, including adding a Bosch pre-filled syringe system that should be validated and online early in 2012. Read more about our 215,000-square-foot facility and equipment on our facilities page.
*does not include beta–lactams or vaccines derived from live organisms